Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
3 other identifiers
interventional
216
1 country
49
Brief Summary
This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy. Mepitel Film may reduce the severity of skin redness and peeling in the area of radiation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jul 2022
Longer than P75 for phase_3
49 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 26, 2021
CompletedFirst Posted
Study publicly available on registry
August 4, 2021
CompletedStudy Start
First participant enrolled
July 26, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 29, 2024
CompletedResults Posted
Study results publicly available
April 29, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 15, 2029
ExpectedApril 29, 2025
April 1, 2025
1.8 years
July 26, 2021
March 31, 2025
April 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Serially Measured Patient-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores
Scores obtained at baseline (i.e. prior to the start of radiation), during weekly radiation therapy, at 10 (±4) days post-radiation therapy, and at 3-months post radiation therapy. At a given measurement time point, a patient-completed mRISRAS score ranges from 0 to 12, where higher scores correspond to increased radiation-induced skin reactions. The effect of the Mepitel Film in reducing the severity of radiation dermatitis will be defined as the between-arm difference in the summary statistic area under the curve obtained from a repeated-measures (means) mixed model.
Up to 5 months
Secondary Outcomes (3)
Centralized, Blinded Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores Obtained From a Blinded Grading of the Photographs Taken at the End of Radiation Therapy
Up to 2 months
Serially Measured Non-blinded Institutional Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores
Up to 5 months
Serially Measured Combined Patient- and Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores
Up to 5 months
Study Arms (2)
Arm I (standard of care)
ACTIVE COMPARATORPatients receive standard of care skin management during radiation therapy for up to 6 weeks.
Arm II (Mepitel Film)
EXPERIMENTALPatients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.
Interventions
Eligibility Criteria
You may qualify if:
- Histologic confirmation of breast malignancy with TNM staging.
- Patients must have undergone a mastectomy with or without reconstruction within the past 120 days if not receiving adjuvant therapy, or within 60 days after completion of the last dose of chemotherapy.
- No prior radiotherapy to any portion of the planned treatment site.
- No documented history of adhesive or tape allergy.
- Patients must be scheduled to receive conventionally fractionated photon-based radiation. Patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation or hypofractionated radiation are not eligible.
- No active rash or pre-existing dermatitis within the treatment field.
- No co-existing medical conditions resulting in life expectancy \< 2 years.
- No active collagen vascular diseases (i.e. lupus erythematosus, scleroderma, dermatomyositis).
- No concomitant cytotoxic chemotherapy. Endocrine therapy and HER2 directed therapies are allowed.
- No current inflammatory breast cancer, or gross dermal involvement at initiation of radiotherapy.
- No previous history of organ or bone marrow transplant.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- In order to complete the mandatory patient-completed measures, participants must be able to speak and read English.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (49)
Fremont - Rideout Cancer Center
Marysville, California, 95901, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California, 96161, United States
Beebe South Coastal Health Campus
Frankford, Delaware, 19945, United States
Helen F Graham Cancer Center
Newark, Delaware, 19713, United States
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713, United States
Beebe Health Campus
Rehoboth Beach, Delaware, 19971, United States
John Fitzgerald Kennedy Medical Center
Atlantis, Florida, 33462, United States
McFarland Clinic - Ames
Ames, Iowa, 50010, United States
Mercy Hospital
Cedar Rapids, Iowa, 52403, United States
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403, United States
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325, United States
Iowa Methodist Medical Center
Des Moines, Iowa, 50309, United States
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309, United States
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314, United States
MaineHealth Coastal Cancer Treatment Center
Bath, Maine, 04530, United States
Maine Medical Center-Bramhall Campus
Portland, Maine, 04102, United States
MaineHealth Cancer Care Center of York County
Sanford, Maine, 04073, United States
Maine Medical Center- Scarborough Campus
Scarborough, Maine, 04074, United States
Anne Arundel Medical Center
Annapolis, Maryland, 21401, United States
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215, United States
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, 21044, United States
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061, United States
UM Saint Joseph Medical Center
Towson, Maryland, 21204, United States
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106, United States
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154, United States
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Delbert Day Cancer Institute at PCRMC
Rolla, Missouri, 65401, United States
Mercy Hospital Springfield
Springfield, Missouri, 65804, United States
Mercy Hospital Saint Louis
St Louis, Missouri, 63141, United States
Billings Clinic Cancer Center
Billings, Montana, 59101, United States
Glens Falls Hospital
Glens Falls, New York, 12801, United States
Dickstein Cancer Treatment Center
White Plains, New York, 10601, United States
Altru Cancer Center
Grand Forks, North Dakota, 58201, United States
Holy Redeemer Hospital and Medical Center
Meadowbrook, Pennsylvania, 19046, United States
AnMed Health Cancer Center
Anderson, South Carolina, 29621, United States
Tidelands Georgetown Memorial Hospital
Georgetown, South Carolina, 29440, United States
Saint Francis Hospital
Greenville, South Carolina, 29601, United States
Saint Francis Cancer Center
Greenville, South Carolina, 29607, United States
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651, United States
MUSC Health Tidelands Health Radiation Therapy Center
Murrells Inlet, South Carolina, 29576, United States
Spartanburg Medical Center
Spartanburg, South Carolina, 29303, United States
Doctor's Hospital of Laredo
Laredo, Texas, 78041, United States
University of Utah Sugarhouse Health Center
Salt Lake City, Utah, 84106, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911, United States
Aspirus Regional Cancer Center
Wausau, Wisconsin, 54401, United States
Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin, 54494, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Kimberly Corbin
- Organization
- Mayo Clinic
Study Officials
- STUDY CHAIR
Kimberly Corbin, MD
Mayo Clinic
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 26, 2021
First Posted
August 4, 2021
Study Start
July 26, 2022
Primary Completion
May 29, 2024
Study Completion (Estimated)
February 15, 2029
Last Updated
April 29, 2025
Results First Posted
April 29, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will share